Skip to main content

Share this:

A Hopeful Approach to Low-Risk Prostate Cancer


A Hopeful Approach to Low-Risk Prostate Cancer

Receiving a prostate cancer diagnosis can be a life-altering experience, often shrouded in fear and uncertainty. However, not all prostate cancers are created equal. A significant number of cases are classified as low-risk, and understanding this distinction can be a game-changer in reclaiming your life and well-being.

According to the American Cancer Society, prostate cancer is the second most common cancer among men in the United States. There were an estimated 248,530 new cases in 2021. But here’s the good news: studies suggest that about 50-70% of these diagnoses are low-risk, meaning the cancer is unlikely to grow or spread quickly.

Defining Low-Risk Prostate Cancer

Low-risk prostate cancer is determined based on three key factors:

1. Gleason Score: This scoring system ranges from 6 to 10 and evaluates the aggressiveness of cancer cells. Low-risk cancers typically have a Gleason score of 6 (3+3) or favorable intermediate 7 (3+4).
2. PSA Levels: Prostate-specific antigen (PSA) is a protein produced by prostate cells. Low-risk prostate cancer is usually associated with PSA levels below 10 ng/mL.
3. Clinical Stage: Determined through physical exams and imaging, low-risk cancers are often confined to the prostate and are classified as T1 or T2a stages.

Embracing Active Surveillance

One of the most common management strategies for low-risk prostate cancer is active surveillance (AS). This involves regularly monitoring PSA levels, digital rectal exams (DRE), multi-parametric MRI’s, and occasional biopsies. The goal is to avoid unnecessary treatment and maintain quality of life, intervening only if the cancer shows signs of progression.

A groundbreaking 2023 study published in the New England Journal of Medicine followed men with localized prostate cancer for 15 years. The results were eye-opening: no significant difference in survival rates between those who underwent active surveillance, surgery, or radiation therapy.

Prostate cancer-specific mortality was low regardless of the treatment assigned, with no significant difference among the three groups (3.1% in the active-monitoring group, 2.2% in the prostatectomy group, and 2.9% in the radiotherapy group). This study reinforces the safety and effectiveness of active surveillance for low-risk prostate cancer.

The study suggests that for men with localized, low or intermediate-risk prostate cancer, the choice of therapy involves weighing the trade-offs between presumed benefits and harms associated with different treatments rather than a clear survival advantage for any one approach.

Benefits of Active Surveillance

Avoidance of Immediate Treatment: Delays or eliminates the need for surgery or radiation, which can have significant side effects.
Maintains Quality of Life: It reduces the risk of treatment-related complications, including incontinence and erectile dysfunction, allowing men to continue with their everyday activities.
High Survival Rates: Studies indicate excellent survival rates for men on active surveillance, with many living for decades without aggressive treatment.

Fear of Missing the “Window” for Treatment

Many men with low-risk prostate cancer fear that waiting might result in missing the best opportunity for treatment. However, research shows that active surveillance is a safe approach for low-risk patients and does not compromise the effectiveness of treatment if it becomes necessary. In fact, AS allows men with low-risk prostate cancer to benefit from any future treatment developments.

Patient Perspectives and Decision Regret

Researchon patient perspectives regarding active surveillance for localized prostate cancer revealed insights into decision-making challenges. Many individuals expressed a strong desire for aggressive treatment, often influenced by a lack of awareness about conservative management options like AS.

Evidence synthesis from 14 studies involving 17,883 patients showed that significant decision regret was present in approximately 20% of cases (95% confidence interval 16-23). Patients who opted for active surveillance (closely monitoring the condition rather than undergoing immediate treatment) reported a lower regret rate at 13%. Those who underwent radiotherapy (treatment using radiation) had a regret rate of 19%, and those who underwent prostatectomy (surgical removal of the prostate) had a regret rate of 18%.

Reducing Decision Regret

To help prevent decision regret and improve outcomes, patients should:

Actively Participate in Decision-Making
Engage in shared decision-making with your healthcare provider. Discuss the available options, as well as their risks and benefits. Actively participating in the process can help you feel more ownership over the decision and reduce regret later.

Seek Information and Ask Questions

Educate yourself about your condition and the proposed treatments. Ask your provider to explain things in plain language, and don’t hesitate to ask for clarification. The more informed you are, the better you can weigh the pros and cons of each option. You need to become your own case manager.

Follow Up with Your Provider

Maintain open communication with your healthcare team. Discuss any concerns or changes in how you’re feeling. They can help address new issues that arise and provide support.


Low-risk prostate cancer, while a serious diagnosis, does not need to be a source of overwhelming fear. By separating facts from fears, men can make informed decisions prioritizing their health and quality of life. Active surveillance offers effective management, ensuring life continues with minimal disruption.

Remember, a diagnosis of low-risk prostate cancer is not a death sentence but an invitation to engage actively in your health and well-being. With ongoing research and advancements in prostate cancer management, the outlook for men with low-risk prostate cancer continues to improve.